Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab.

Journal

Targeted oncology

ISSN: 1776-260X

Titre abrégé: Target Oncol

Pays: France

ID NLM: 101270595

Informations de publication

Date de publication:
12 Feb 2024

Historique:

accepted: 04 01 2024

medline: 12 2 2024

pubmed: 12 2 2024

entrez: 12 2 2024

Statut: aheadofprint

Résumé

The results reported in the TOPAZ-1 phase III trial led to the approval of the combination of cisplatin and gemcitabine with durvalumab as the new first-line standard of care for patients with locally advanced or metastatic cholangiocarcinoma. We performed a clustering analysis to classify patients into different groups based on their mutation profile, correlating the results of the analysis with clinical outcomes. We selected 51 patients with cholangiocarcinoma who were treated with the combination of chemotherapy and durvalumab and who were screened using the next-generation sequencing-based FoundationOne gene panel. We conducted mutation-based clustering of tumors and a survival analysis. Three main clusters were identified. Cluster 1 is mostly characterized by mutations in genes belonging to the chromatin modification pathway, altered in 100% of patients. Cluster 2 is characterized by the alteration of several pathways, among which DNA damage control, chromatin modification, RTK/RAS, cell-cycle apoptosis, TP53, and PI3K were the most affected. Finally, most altered pathways in cluster 3 were RTK/RAS and cell-cycle apoptosis. Overall response rate was 4/13 (31%), 12/24 (50%), and 0/10 (0%) in cluster 1, cluster 2, and cluster 3, respectively, and the difference between the three clusters was statistically significant (p = 0.0188). By grouping patients into three clusters with distinct molecular and genomic alterations, our analysis showed that patients included in cluster 2 had higher overall response rates, whereas patients included in cluster 3 had no objective response. Further investigations on larger and external cohorts are needed in order to validate our results.

Sections du résumé

BACKGROUND BACKGROUND

OBJECTIVE OBJECTIVE

We performed a clustering analysis to classify patients into different groups based on their mutation profile, correlating the results of the analysis with clinical outcomes.

METHODS METHODS

We selected 51 patients with cholangiocarcinoma who were treated with the combination of chemotherapy and durvalumab and who were screened using the next-generation sequencing-based FoundationOne gene panel. We conducted mutation-based clustering of tumors and a survival analysis.

RESULTS RESULTS

Three main clusters were identified. Cluster 1 is mostly characterized by mutations in genes belonging to the chromatin modification pathway, altered in 100% of patients. Cluster 2 is characterized by the alteration of several pathways, among which DNA damage control, chromatin modification, RTK/RAS, cell-cycle apoptosis, TP53, and PI3K were the most affected. Finally, most altered pathways in cluster 3 were RTK/RAS and cell-cycle apoptosis. Overall response rate was 4/13 (31%), 12/24 (50%), and 0/10 (0%) in cluster 1, cluster 2, and cluster 3, respectively, and the difference between the three clusters was statistically significant (p = 0.0188).

CONCLUSIONS CONCLUSIONS

By grouping patients into three clusters with distinct molecular and genomic alterations, our analysis showed that patients included in cluster 2 had higher overall response rates, whereas patients included in cluster 3 had no objective response. Further investigations on larger and external cohorts are needed in order to validate our results.

Identifiants

DOI: 10.1007/s11523-024-01032-5 PMID: 38345693

pubmed: 38345693

doi: 10.1007/s11523-024-01032-5

pii: 10.1007/s11523-024-01032-5

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Rimini M, Puzzoni M, Pedica F, Silvestris N, Fornaro L, Aprile G, et al. Cholangiocarcinoma: new perspectives for new horizons. Expert Rev Gastroenterol Hepatol. 2021;15(12):1367–83. https://doi.org/10.1080/17474124.2021.1991313 .

doi: 10.1080/17474124.2021.1991313 pubmed: 34669536

Wu J, Yang S, Xu K, Ding C, Zhou Y, Fu X, et al. Patterns and trends of liver cancer incidence rates in Eastern and Southeastern Asian countries (1983–2007) and predictions to 2030. Gastroenterology. 2018;154(6):1719-28.e5. https://doi.org/10.1053/j.gastro.2018.01.033 .

doi: 10.1053/j.gastro.2018.01.033 pubmed: 29549041

Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag HB, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71(1):104–14. https://doi.org/10.1016/j.jhep.2019.03.013 .

doi: 10.1016/j.jhep.2019.03.013 pubmed: 30910538

Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152:745–61.

doi: 10.1053/j.gastro.2016.11.048 pubmed: 28043904

Mazzaferro V, Gorgen A, Roayaie S, DrozDitBusset M, Sapisochin G. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72(2):364–77. https://doi.org/10.1016/j.jhep.2019.11.020 .

doi: 10.1016/j.jhep.2019.11.020 pubmed: 31954498

Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81. https://doi.org/10.1056/NEJMoa0908721 .

doi: 10.1056/NEJMoa0908721 pubmed: 20375404

Vogel A, Bridgewater J, Edeline J, Kelley RK, Klümpen HJ, Malka D, ESMO Guidelines Committee, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127–40. https://doi.org/10.1016/j.annonc.2022.10.506 .

doi: 10.1016/j.annonc.2022.10.506 pubmed: 36372281

Lamarca A, Kapacee Z, Breeze M, Bell C, Belcher D, Staiger H, et al. Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers. J Clin Med. 2020;9(9):2854. https://doi.org/10.3390/jcm9092854 .

doi: 10.3390/jcm9092854 pubmed: 32899345 pmcid: 7563385

Rimini M, Loi E, Fabregat-Franco C, Burgio V, Lonardi S, Niger M, et al. Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters. Eur J Cancer. 2022;175:299–310. https://doi.org/10.1016/j.ejca.2022.08.026 .

doi: 10.1016/j.ejca.2022.08.026 pubmed: 36182816

Rimini M, Fabregat-Franco C, Burgio V, Lonardi S, Niger M, Scartozzi M, et al. Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma. Sci Rep. 2022;12(1):18775. https://doi.org/10.1038/s41598-022-22543-z .

doi: 10.1038/s41598-022-22543-z pubmed: 36335135 pmcid: 9637171

Rimini M, Macarulla T, Burgio V, Lonardi S, Niger M, Scartozzi M, et al. Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma. Eur J Cancer. 2022;171:232–41. https://doi.org/10.1016/j.ejca.2022.05.004 .

doi: 10.1016/j.ejca.2022.05.004 pubmed: 35749808

Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003–10. https://doi.org/10.1038/ng.3375 .

doi: 10.1038/ng.3375 pubmed: 26258846

Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. NEJM Evid. 2022. https://doi.org/10.1056/EVIDoa2200015 .

doi: 10.1056/EVIDoa2200015 pubmed: 38319896

Valle JW, Qin S, Antonuzzo L, Tougeron D, Lee C, et al. Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC). Ann Oncol. 2022;33(Suppl_9):S1454–84. https://doi.org/10.1016/annonc/annonc1123 .

Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;S0140–6736(23):00727–34. https://doi.org/10.1016/S0140-6736(23)00727-4 .

doi: 10.1016/S0140-6736(23)00727-4

Zhang W, Flemington EK, Zhang K. Driver gene mutations based clustering of tumors: methods and applications. Bioinformatics. 2018;34(13):i404–11. https://doi.org/10.1093/bioinformatics/bty232 .

doi: 10.1093/bioinformatics/bty232 pubmed: 29950003 pmcid: 6022677

Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546–58. https://doi.org/10.1126/science.1235122 .

doi: 10.1126/science.1235122 pubmed: 23539594 pmcid: 3749880

Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in The Cancer Genome Atlas. Cell. 2018;173(2):321-37.e10. https://doi.org/10.1016/j.cell.2018.03.035 .

doi: 10.1016/j.cell.2018.03.035 pubmed: 29625050 pmcid: 6070353

Shroff RT, Guthrie KA, Scott AJ, et al. SWOG 1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. J Clin Oncol. 2023;41(Suppl 4):LBA490. https://doi.org/10.1200/JCO.2023.41.3_suppl.LBA490 .

doi: 10.1200/JCO.2023.41.3_suppl.LBA490

Watkins JA, Irshad S, Grigoriadis A, Tutt AN. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res. 2014;16:211.

doi: 10.1186/bcr3670 pubmed: 25093514 pmcid: 4053155

Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Canc. 2004;4:814e9.

doi: 10.1038/nrc1457

Muggia F, Safra T. ‘BRCAness’ and its implications for platinum action in gynecologic cancer. Anticancer Res. 2014;34:551–6.

pubmed: 24510983 pmcid: 4682661

Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–7. https://doi.org/10.1038/nature03443 .

doi: 10.1038/nature03443 pubmed: 15829966

Wattenberg MM, Asch D, Yu S, O’Dwyer PJ, Domchek SM, Nathanson KL, et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer. 2020;122(3):333–9. https://doi.org/10.1038/s41416-019-0582-7 .

doi: 10.1038/s41416-019-0582-7 pubmed: 31787751

Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317–27. https://doi.org/10.1056/NEJMoa1903387 .

doi: 10.1056/NEJMoa1903387 pubmed: 31157963 pmcid: 6810605

O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60(4):547–60. https://doi.org/10.1016/j.molcel.2015.10.040 .

doi: 10.1016/j.molcel.2015.10.040 pubmed: 26590714

Chatzinikolaou G, Karakasilioti I, Garinis GA. DNA damage and innate immunity: links and trade-offs. Trends Immunol. 2014;35(9):429–35. https://doi.org/10.1016/j.it.2014.06.003 .

doi: 10.1016/j.it.2014.06.003 pubmed: 25023467

Mouw KW, Goldberg MS, Konstantinopoulos PA, D’Andrea AD. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov. 2017;7(7):675–93. https://doi.org/10.1158/2159-8290.CD-17-0226 .

doi: 10.1158/2159-8290.CD-17-0226 pubmed: 28630051 pmcid: 5659200

Nastasi C, Mannarino L, D’Incalci M. DNA damage response and immune defense. Int J Mol Sci. 2020;21(20):7504. https://doi.org/10.3390/ijms21207504 .

doi: 10.3390/ijms21207504 pubmed: 33053746 pmcid: 7588887

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–4. https://doi.org/10.1126/science.1129139 .

doi: 10.1126/science.1129139 pubmed: 17008531